{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.96","value":"17.4"}]}],"title":"Baseline SJC (n = 2047)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.43","value":"8.2"}]}],"title":"Week 24 SJC (n = 2010)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.75","value":"6.4"}]}],"title":"Week 48 SJC (n = 1924)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.69","value":"4.2"}]}],"title":"Week 108 SJC (n = 1692)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.09","value":"4.0"}]}],"title":"Week 156 SJC (n = 1580)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.96","value":"3.2"}]}],"title":"Week 204 SJC (n = 1482)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.85","value":"2.9"}]}],"title":"Week 264 SJC (n = 1352)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.97","value":"27.3"}]}],"title":"Baseline TJC (n = 2047)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.10","value":"12.8"}]}],"title":"Week 24 TJC (n = 2010)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.99","value":"10.3"}]}],"title":"Week 48 TJC (n = 1924)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.04","value":"7.8"}]}],"title":"Week 108 TJC (n = 1692)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.03","value":"7.2"}]}],"title":"Week 156 TJC (n = 1580)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.83","value":"6.1"}]}],"title":"Week 204 TJC (n = 1482)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.48","value":"5.6"}]}],"title":"Week 264 TJC (n = 1352)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2067"}],"units":"Participants"}],"description":"The number of swollen (66 assessed joints) and tender (68 assessed joints) joints was assessed. Joints were physically examined and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"MEAN","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants with available data were included in the analysis.","timeFrame":"Baseline to Week 264","title":"Swollen and Tender Joint Count (SJC/TJC) at Baseline and Weeks 24, 48, 108, 156, 204, and 264","type":"SECONDARY","unitOfMeasure":"Joints"}